Prognostic significance of p16 protein in pancreatic ductal adenocarcinoma

Iwatate,Yosuke; Hoshino,Isamu; Ishige,Fumitaka; Itami,Makiko; Chiba,Satoshi; Arimitsu,Hidehito; Yanagibashi,Hiroo; Nagase,Hiroki; Yokota,Hajime; Takayama,Wataru

doi:10.3892/mco.2020.2047

Prognostic significance of p16 protein in pancreatic ductal adenocarcinoma

Authors:
- Yosuke Iwatate
- Isamu Hoshino
- Fumitaka Ishige
- Makiko Itami
- Satoshi Chiba
- Hidehito Arimitsu
- Hiroo Yanagibashi
- Hiroki Nagase
- Hajime Yokota
- Wataru Takayama
View Affiliations

Affiliations: Division of Hepato‑Biliary‑Pancreatic Surgery, Chiba Cancer Center, Chuo‑ku, Chiba 260‑8717, Japan, Division of Gastroenterological Surgery, Chiba Cancer Center, Chuo‑ku, Chiba 260‑8717, Japan, Division of Clinical Pathology, Chiba Cancer Center, Chuo‑ku, Chiba 260‑8717, Japan, Laboratory of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba Cancer Center, Chuo‑ku, Chiba 260‑8717, Japan, Department of Radiology, Graduate School of Medicine, Chiba University, Chuo‑ku, Chiba 260‑8670, Japan
Published online on: May 18, 2020 https://doi.org/10.3892/mco.2020.2047
Pages: 83-91

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The p16 gene, which is also known as CDKN2A, INK4A, or CDK4I, and its products that are known to be cell cycle inhibitors and tumor suppressors have been reported to be altered in various human tumor types. Altered p16 has been indicated to be correlated with negative p16 expression using immunohistochemistry (IHC). However, its association with the prognosis remains controversial because the findings of previous studies are inconsistent. The current study evaluated the relationship between the expression levels of p16 and the clinicopathological features associated with prognosis in patients with primary pancreatic ductal adenocarcinomas (PDACs). From January 2013 to December 2017, tissues of 103 PDAC patients who had undergone elective pancreatic resection were obtained and assessed for p16 expression by IHC. No correlation was observed between p16 status and clinicopathological factors (P>0.05). Notably, negative p16 expression on IHC was not significantly associated with poor prognosis using the Kaplan‑Meier method.

View Figures

View References

1	Spath C, Nitsche U, Muller T, Michalski C, Erkan M, Kong B and Kleeff J: Strategies to improve the outcome in locally advanced pancreatic cancer. Minerva Chir. 70:97–106. 2015.PubMed/NCBI
2	Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, et al: Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 518:495–501. 2015.PubMed/NCBI View Article : Google Scholar
3	Balachandran VP, Luksza M, Zhao JN, Makarov V, Moral JA, Remark R, Herbst B, Askan G, Bhanot U, Senbabaoglu Y, et al: Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 551:512–516. 2017.PubMed/NCBI View Article : Google Scholar
4	Russo AA, Tong L, Lee JO, Jeffrey PD and Pavletich NP: Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature. 395:237–243. 1998.PubMed/NCBI View Article : Google Scholar
5	Schlitter AM, Segler A, Steiger K, Michalski CW, Jäger C, Konukiewitz B, Pfarr N, Endris V, Bettstetter M, Kong B, et al: Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes. Sci Rep. 7(41064)2017.PubMed/NCBI View Article : Google Scholar
6	Ryan DP, Hong TS and Bardeesy N: Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014.PubMed/NCBI View Article : Google Scholar
7	Attri J, Srinivasan R, Majumdar S, Radotra BD and Wig J: Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma. BMC Gastroenterol. 5(22)2005.PubMed/NCBI View Article : Google Scholar
8	Ohtsubo K, Watanabe H, Yamaguchi Y, Hu YX, Motoo Y, Okai T and Sawabu N: Abnormalities of tumor suppressor gene p16 in pancreatic carcinoma: Immunohistochemical and genetic findings compared with clinicopathological parameters. J Gastroenterol. 38:663–671. 2003.PubMed/NCBI View Article : Google Scholar
9	Moskaluk CA, Hruban RH and Kern SE: p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res. 57:2140–2143. 1997.PubMed/NCBI
10	Sellers WR, Rodgers JW and Kaelin WG Jr: A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. Proc Natl Acad Sci USA. 92:11544–11548. 1995.PubMed/NCBI View Article : Google Scholar
11	Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ and Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 8:27–32. 1994.PubMed/NCBI View Article : Google Scholar
12	Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, et al: Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 57:3126–3130. 1997.PubMed/NCBI
13	Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH and Goggins M: Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 60:1835–1839. 2000.PubMed/NCBI
14	Oshima M, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y and Yachida S: Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg. 258:336–346. 2013.PubMed/NCBI View Article : Google Scholar
15	Masetti M, Acquaviva G, Visani M, Tallini G, Fornelli A, Ragazzi M, Vasuri F, Grifoni D, Di Giacomo S, Fiorino S, et al: Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. Cancer Biomark. 21:323–334. 2018.PubMed/NCBI View Article : Google Scholar
16	Jeong J, Park YN, Park JS, Yoon DS, Chi HS and Kim BR: Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer. Yonsei Med J. 46:519–525. 2005.PubMed/NCBI View Article : Google Scholar
17	Larque AB, Conde L, Hakim S, Alos L, Jares P, Vilaseca I, Cardesa A and Nadal A: P16(INK⁴a) overexpression is associated with CDKN2A mutation and worse prognosis in HPV-negative laryngeal squamous cell carcinomas. Virchows Arch. 466:375–382. 2015.PubMed/NCBI View Article : Google Scholar
18	Zhao W, Huang CC, Otterson GA, Leon ME, Tang Y, Shilo K and Villalona MA: Altered p16(INK4) and RB1 expressions are associated with poor prognosis in patients with nonsmall cell lung cancer. J Oncol. 2012(957437)2012.PubMed/NCBI View Article : Google Scholar
19	Lam AK, Ong K, Giv MJ and Ho YH: p16 expression in colorectal adenocarcinoma: Marker of aggressiveness and morphological types. Pathology. 40:580–585. 2008.PubMed/NCBI View Article : Google Scholar
20	Milde-Langosch K, Bamberger AM, Rieck G, Kelp B and Loning T: Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat. 67:61–70. 2001.PubMed/NCBI View Article : Google Scholar
21	Yachida S, White CM, Naito Y, Zhong Y, Brosnan JA, Macgregor-Das AM, Morgan RA, Saunders T, Laheru DA, Herman JM, et al: Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin Cancer Res. 18:6339–6347. 2012.PubMed/NCBI View Article : Google Scholar
22	Cancer Genome Atlas Research Network. Electronic address: uriandrew_aguirre@dfci.harvard.edusimpleandrew_aguirre@dfci.harvard.edu; Cancer Genome Atlas Research Network: Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32: 185-203.e13, 2017.